Global Trial in APG2575 for Patients With CLL/SLL
ConditionCLL/SLL
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-99
SponsorAscentage Pharma Group Inc.
About this trial
This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors
Eligibility criteria
Qualifiers
Age ≥ 18 years.
Patients that have documented CLL/SLL who meet iwCLL 2018 criteria for CLL treatment guidelines are eligible for treatment and must be receiving BTKi monotherapy for at least 12 months
ECOG Performance Status grade 0-2
Absolute neutrophil count ≥ 1.0 × 109/L
Disqualifiers
None
Trial design
Treatments tested in this trial
- lisaftoclax +BTK inhibitor
- BTK inhibitor
Treatment groups
400 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov